| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We have elucidated the molecular mechanisms of carcinogenesis, proliferation and progression of billiary tract carcinoma (BTC) using numerous BTC-related bio-resources. As a result, four candidate genes associated with different sites of tumor locations were found and immunohistochemical study using surgical specimens confirmed the consistency of their expression with the tumor existing sites. Analysis of 50 candidate genes associated with IDCC (Intraductal Carcinoma Component) as one of the histopathological BTC spreading and malignancy factors revealed that many highly expressed genes in the tumor group without IDCC (high-grade group) were involved in tumor malignancy related with metastasis or invasion. This data supported the clinicopathological features of IDCC. Furthermore, we have established in vitro assay system of BTC that enables preclinical study and appropriates parameters for novel anticancer drugs which targeting the above genes.
|
